

Dr Jeff Davies appointed as non-executive director

Melbourne, Australia; 24 February 2022: Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.

Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.

Dr Davies was part of CSL's due diligence teams which led to the acquisitions of Plasma Fractionation businesses of the Swiss Red Cross (2000) and Aventis Behring (2003) thus transforming CSL into a global company.

As Global Head of Plasma Product Research and Development at CSL-Behring, Dr Davies was responsible for CSL's plasma product R&D strategy and programs conducted in Switzerland, Germany, Australia, USA and Japan. In this role he oversaw and played an important role in the development of leading products, including the multi-billion-dollar Privigen® immunoglobulin product.

As Executive Vice President & General Manager at CSL for the Asia-Pacific region, Dr Davies had commercial and operational responsibility for the Asia-Pacific region. In this role, he oversaw the pharmaceutical, plasma, vaccine, and diagnostic businesses, employing over 1200 staff, in Australia (including the Broadmeadows and Parkville sites), China, and Asia-Pacific.

During his 30-year career at CSL, Dr Davies also held senior executive roles in R&D, regulatory affairs, clinical research, and medical affairs. Dr Davies is also a partner and founding director of the pharmaceutical consulting firm Centre for Biopharmaceutical Excellence.

Starpharma's Chairman, Mr Rob Thomas said: "We are delighted to have Jeff join Starpharma as a non-executive director. He has deep operational expertise in the international pharmaceutical industry, with a track record of bringing highly successful products to market. Jeff's extensive international R&D, regulatory, clinical, operations and commercial experience will be of great value to Starpharma through its next phase of growth."

Dr Jeff Davies said: "I am very excited to join Starpharma's board, having followed and admired the company for some years. Starpharma has an impressive commercial and development pipeline based on its proprietary dendrimer platform, with multiple high-value assets in the clinic and on market. I look forward to contributing to Starpharma's future success."

Dr Davies holds a PhD in Biochemistry from Monash University and is a Graduate of the Senior Executive Program from the London Business School.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP[®] drug delivery and VivaGel[®]. Starpharma has developed VIRALEZE[™], an antiviral nasal spray that is registered for sale in the Europe, Vietnam, India, Saudi Arabia, and New Zealand, and available outside Australia in certain markets online. VIRALEZE[™] is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel[®] condom and VivaGel[®] BV. VivaGel[®] products have been licensed in >160 countries, are registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP[®], is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP[®] versions of existing drugs, particularly in the area of anti-cancer therapies. DEP[®] partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

Starpharma.com | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.